Publicly listed biopharma company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system & gut microbiome
Immuron Limited (ASX:IMC) (NASDAQ:IMRN) has continued to expand its presence in the digestive health market through growing sales, commercialisation activities, and portfolio expansion initiatives.
https://t.co/Yvc9ihXhEB
#NASDAQ#IMRN#IMC#ASX#KalkineMediaAU#Immuron
We've just posted the following update on our investor hub: Emerging Growth Conference 92 - 8th May 2026: Immuron Limited (NASDAQ:IMRN)
Check out the full update and join in with the conversation at: https://t.co/oNww1PQxw1
#ASX#IMC#NASDAQ#IMRN
We've just released the following announcement: Emerging Growth Conference
Check out the full announcement and join in with the conversation at: https://t.co/BwOlfxJ7KX
#imc
$IMRN Live Emerging Growth Conference 92 - May 6 & 7
@ImmuronLtd
Register:
https://t.co/EJvB65yFbY
Questions for the Company? [email protected]
To Present on the Conference:
305-330-1985
[email protected]
We've just released the following announcement: Immuron Double Digit 3Q Sales Growth
Check out the full announcement and join in with the conversation at: https://t.co/fJXKF8nXc9
#imc
We've just released the following announcement: Small Holding Share Sale Facility
Check out the full announcement and join in with the conversation at: https://t.co/F2tQwS75Le
#imc
Immuron CEO Steven Lydeamore outlines strategic pivot to partnering model for IMM-124E and IMM-529, targeting @ImmuronLtd $IMC profitability.
https://t.co/zbVcWlM6Dy
We've just released the following announcement: Presentation to Coffee Microcaps Conference
Check out the full announcement and join in with the conversation at: https://t.co/zYkBZ5NuhD
#imc
FDA greenlight: @ImmuronLtd secures approval for IMM-529 C. diff trial targeting US$400M peak sales opportunity as global sales hit $4.2M, up 5%. $IMC
https://t.co/phIkk8QXzU
@ImmuronLtd secures FDA approval to trial its C-diff infection drug while posting 5% global sales growth to $4.2M in HY26. $IMC ⚡
We've broken down the full announcement in the video above.
Highlights:
👉 $10M cash on hand = 23.5 months runway
#ASX#StockMarket#Investing
We've just released the following announcement: Strategic Update and HY26 Results
Check out the full announcement and join in with the conversation at: https://t.co/0TeiH3EBnd
#imc
We've just released the following announcement: Appendix 4D and Half Year Report
Check out the full announcement and join in with the conversation at: https://t.co/5JVrLn4bi6
#imc
@EmergingGrowthC@EmergingGrowth1@ImmuronLtd Emerging Growth Research releases a flash report on $IMRN with a $3.50 price target. The report can be viewed here:
https://t.co/2hT32ad2M0
We've just released the following announcement: Emerging Growth Conference Presentation
Check out the full announcement and join in with the conversation at: https://t.co/9bqenleBc8
#imc
We've just released the following announcement: Immuron Continued Sales Growth
Check out the full announcement and join in with the conversation at: https://t.co/pAyjuTcqLG
#imc
$IMRN Live Emerging Growth Conference 89 - January 21 & 22
@ImmuronLtd
Register:
https://t.co/H5qTJSrbJV
Questions for the Company? [email protected]
To Present on the Conference:
305-330-1985
[email protected]